• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genetic Technologies Ltd

    11/20/24 8:00:07 AM ET
    $GENE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GENE alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    FORM 6-K

    U.S. SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of November , 2024

     

    Commission File Number 0-51504

     

    GENETIC TECHNOLOGIES LIMITED

    (Exact Name as Specified in its Charter)

     

    N/A

    (Translation of Registrant’s Name)

     

    Suite 7, Level 1, 321 Chapel Street

    Prahran Victoria 3181 Australia

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

    This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement on Form F-3 (File Nos. 333-276168), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

     

     

     
     

     

    Exhibit Index

     

    Exhibit No.   Description
         
    Exhibit 99.1   Appointment of Voluntary Administrators to Genetic Technologies Limited

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: November 20, 2024

     

    GENETIC TECHNOLOGIES LIMITED  
       
    By: /s/ Mark Ziirsen  
    Name: Mark Ziirsen  
    Title: Company Secretary  

     

     

    Get the next $GENE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GENE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GENE
    SEC Filings

    See more
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/12/24 8:00:15 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/2/24 8:00:04 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      11/20/24 8:00:07 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care